Journal of Shanghai Jiao Tong University (Medical Science) >

2022 , Vol. 42 >Issue 1: 113 - 118

DOI: https://doi.org/10.3969/j.issn.1674-8115.2022.01.017

Review

Research progress of botulinum toxin A in treatment of neurogenic bladder

  • Lin ZHANG ,
  • Zhong CHEN
Expand
  • Department of Urology, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai 200233, China
CHEN Zhong, E-mail: csy2000777@sina.com.

Received date: 2021-07-27

  Online published: 2022-01-28

Supported by

Project of Shanghai Municipal Commission of Health and Family Planning(20174011)

Fold

Abstract

In recent years, intradetrusor injection of botulinum toxin A (BTX-A) has achieved satisfactory therapeutic effects on the treatment of neurogenic bladder, improving the bladder function and reducing the lower urinary tract symptoms while improving patients' quality of life. In addition, this therapy has advantages including minimal invasiveness, mild side effects, and allowing repeated injections. At present, there is no international consensus on the injection plan for BTX-A. Therefore, based on the recent clinical research results, this paper reviews the mechanism of action, types, usage, therapeutic effects, influencing factors, as well as adverse reactions and contraindications of BTX-A, in an attempt to provide evidence for its clinical application.

Key words： botulinum toxin A; neurogenic bladder; neurogenic detrusor overactivity

Cite this article

Lin ZHANG , Zhong CHEN . Research progress of botulinum toxin A in treatment of neurogenic bladder[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022 , 42(1) : 113 -118 . DOI: 10.3969/j.issn.1674-8115.2022.01.017

References

1 孙颖浩, 黄健. 中国泌尿外科和男科疾病诊断治疗指南[M]. 北京: 科学出版社, 2020.
2 MICHEL F, CICERON C, BERNUZ B, et al. Botulinum toxin type A injection after failure of augmentation enterocystoplasty performed for neurogenic detrusor overactivity: preliminary results of a salvage strategy. the ENTEROTOX study[J]. Urology, 2019, 129: 43-47.
3 GROEN J, PANNEK J, CASTRO DIAZ D, et al. Summary of European association of urology (EAU) guidelines on neuro-urology[J]. Eur Urol, 2016, 69(2): 324-333.
4 WECKX F, TUTOLO M, DE RIDDER D, et al. The role of botulinum toxin A in treating neurogenic bladder[J]. Transl Androl Urol, 2016, 5(1): 63-71.
5 JHANG J F, KUO H C. Botulinum toxin A and lower urinary tract dysfunction: pathophysiology and mechanisms of action[J]. Toxins (Basel), 2016, 8(4): 120.
6 RAVENNI R, DE GRANDIS D, MAZZA A. Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence[J]. Neurol Sci, 2013, 34(7): 1043-1048.
7 马英, 胡细枚, 袁裕钧, 等. A型肉毒毒素治疗偏侧面肌痉挛临床分析[J]. 实用药物与临床, 2016, 19(5): 584-587.
8 郑琳, 唐欣. A型肉毒毒素治疗偏侧面肌痉挛57例临床探讨[J]. 中外医疗, 2015, 34(4): 91-92.
9 PEYRONNET B, ROUMIGUIé M, CASTEL-LACANAL E, et al. Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity[J]. Neurourol Urodyn, 2016, 35(2): 267-270.
10 KUO H C. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity[J]. J Urol, 2007, 178(4 pt 1): 1359-1363.
11 APOSTOLIDIS A, DASGUPTA P, DENYS P, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report[J]. Eur Urol, 2009, 55(1): 100-119.
12 CHEN H, XIE K, JIANG C. A single-blind randomized control trial of trigonal versus nontrigonal botulinum toxin-A injections for patients with urinary incontinence and poor bladder compliance secondary to spinal cord injury[J]. J Spinal Cord Med, 2021, 44(5): 757-764.
13 ALLOUSSI S H, LANG C H, EICHEL R, et al. Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment[J]. World J Urol, 2012, 30(3): 367-373.
14 DAVIS N F, BURKE J P, REDMOND E J, et al. Trigonal versus extratrigonal botulinum toxin-A: a systematic review and meta-analysis of efficacy and adverse events[J]. Int Urogynecol J, 2015, 26(3): 313-319.
15 GRISE P, RUFFION A, DENYS P, et al. Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses[J]. Eur Urol, 2010, 58(5): 759-766.
16 KREBS J, PANNEK J, RADEMACHER F, et al. Are 200 units of onabotulinumtoxin A sufficient for the suppression of neurogenic detrusor overactivity in individuals with established 300-unit botulinum toxin treatment? A retrospective cohort study[J]. World J Urol, 2021, 39(2): 543-547.
17 ZHOU X, YAN H L, CUI Y S, et al. Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis[J]. Chin Med J (Engl), 2015, 128(7): 963-968.
18 LEITNER L, GUGGENBüHL-ROY S, KNüPFER S C, et al. More than 15 years of experience with intradetrusor onabotulinum toxin A injections for treating refractory neurogenic detrusor overactivity: lessons to be learned[J]. Eur Urol, 2016, 70(3): 522-528.
19 AVALLONE M A, SACK B S, EL-ARABI A, et al. Less is more-A pilot study evaluating one to three intradetrusor sites for injection of onabotulinum toxin A for neurogenic and idiopathic detrusor overactivity[J]. Neurourol Urodyn, 2017, 36(4): 1104-1107.
20 LIAO C H, CHEN S F, KUO H C. Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: a prospective randomized comparative study[J]. Neurourol Urodyn, 2016, 35(6): 717-723.
21 DENYS P, POPOLO GDEL, AMARENCO G, et al. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport? (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): a randomised placebo-controlled phase Ⅱa study[J]. Neurourol Urodyn, 2017, 36(2): 457-462.
22 RAHNAMA'I M S, MARCELISSEN T A T, BRIERLEY B, et al. Long-term compliance and results of intravesical botulinum toxin A injections in male patients[J]. Neurourol Urodyn, 2017, 36(7): 1855-1859.
23 HEBERT K P, KLARSKOV N, BAGI P, et al. Long term continuation with repeated Botulinum toxin A injections in people with neurogenic detrusor overactivity after spinal cord injury[J]. Spinal Cord, 2020, 58(6): 675-681.
24 O'CONNOR R C, JOHNSON D P, GURALNICK M L. Intradetrusor botulinum toxin injections (300 units) for the treatment of poorly compliant bladders in patients with adult neurogenic lower urinary tract dysfunction[J]. Neurourol Urodyn, 2020, 39(8): 2322-2328.
25 PEYRONNET B, ROUMIGUIé M, CASTEL-LACANAL E, et al. Efficacy and safety of the first and repeated intradetrusor injections of abobotulinum toxin A 750 U for treating neurological detrusor overactivity[J]. World J Urol, 2016, 34(5): 755-761.
26 PEYRONNET B, CASTEL-LACANAL E, MANUNTA A, et al. Failure of botulinum toxin injection for neurogenic detrusor overactivity: switch of toxin versus second injection of the same toxin[J]. Int J Urol, 2015, 22(12): 1160-1165.
27 DASGUPTA R, MURPHY F L. Botulinum toxin in paediatric urology: a systematic literature review[J]. Pediatr Surg Int, 2009, 25(1): 19-23.
28 NAQVI S, CLOTHIER J, WRIGHT A, et al. Urodynamic outcomes in children after single and multiple injections for overactive and low compliance neurogenic bladder treated with abobotulinum toxin A[J]. J Urol, 2020, 203(2): 413-419.
29 DANACIOGLU Y O, KESER F, ERSOZ C, et al. Factors predicting the success of intradetrusor onabotulinum toxin-A treatment in children with neurogenic bladders due to myelomeningocele: the outcomes of a large cohort[J]. J Pediatr Urol, 2021, 17(4): 520.e1-520.e7.
30 HASCOET J, PEYRONNET B, FORIN V, et al. Intradetrusor injections of botulinum toxin type A in children with spina bifida: a multicenter study[J]. Urology, 2018, 116: 161-167.
31 SMITH M C, STRINE A C, DEFOOR W R, et al. Need for botulinum toxin injection and bladder augmentation after isolated bladder outlet procedure in pediatric patients with myelomeningocele[J]. J Pediatr Urol, 2020, 16(1): 32.e1-32.e8.
32 PEYRONNET B, EVEN A, CAPON G, et al. Intradetrusor injections of botulinum toxin A in adults with spinal dysraphism[J]. J Urol, 2018, 200(4): 875-880.
33 áLVARES R A, ARAúJO I D, SANCHES M D. A pilot prospective study to evaluate whether the bladder morphology in cystography and/or urodynamic may help predict the response to botulinum toxin a injection in neurogenic bladder refractory to anticholinergics[J]. BMC Urol, 2014, 14: 66.
34 KIM S W, CHOI J H, LEE Y S, et al. Preoperative urodynamic factors predicting outcome of botulinum toxin-A intradetrusor injection in children with neurogenic detrusor overactivity[J]. Urology, 2014, 84(6): 1480-1484.
35 GUTIéRREZ-MARTíN P, VíRSEDA-CHAMORRO M, SALINAS CASADO J, et al. Factors that influence the urodynamic results of botulinum toxin in the treatment of neurogenic hyperactivity[J]. Actas Urol Esp, 2015, 39(4): 217-221.
36 LI G P, WANG X Y, ZHANG Y. Efficacy and safety of onabotu-linum toxin A in patients with neurogenic detrusor overactivity caused by spinal cord injury: a systematic review and meta-analysis[J]. Int Neurourol J, 2018, 22(4): 275-286.
37 MOORE D C, COHN J A, DMOCHOWSKI R R. Use of botulinum toxin A in the treatment of lower urinary tract disorders: a review of the literature[J]. Toxins (Basel), 2016, 8(4): 88.
38 中华医学会泌尿外科学分会尿控学组. 肉毒毒素治疗下尿路功能障碍中国专家共识[J]. 中华泌尿外科杂志, 2021, 42(6): 405-410.
Options
Outlines

/

〈 〉